Quintiles Launches Integrated Asset Development Planning

Article

Applied Clinical Trials

Potential assets that could benefit from this new offering include small molecule drugs, biologics, medical devices, combination therapies and novel technologies.

Quintiles announced the launch of its Integrated Asset Development Plan (IADP) offering. This new suite of services combines development strategy, regulatory strategy, market and patient access and commercial expertise, with in-depth therapeutic knowledge, a facilitated strategic-planning process, data analytics and modeling to deliver an integrated asset-development plan.

IADP brings together cross-functional strategies and operational delivery to enable more informed decisions that speed market access, fulfill regulatory requirements and help optimize commercial potential. Potential assets that could benefit from this new offering include small molecule drugs, biologics, medical devices, combination therapies and novel technologies.

Read the full release.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.